ESG News For Medincell SA

Institutional Shareholder Services (ISS) awarded MedinCell a “Prime” Environmental, Social, and Governance (ESG) rating.Rating places MedinCell among the top 10% in the Pharmaceuticals & Biotechnology sector. ISS, one of the world’s leading ratings agencies for sustainable investments, provides a highly relevant, material assessment of ESG performance to investors.MedinCell is a pharmaceutical technology company with 150 employees from 30 nationalities, all shareholders.  The first product based on MedinCell’s long-acting injectable technology should get FDA market approval by April 2023, two additional products are in phase 3, and a pipe of other products follows.Access here the complete press release